Runda Medical provides substantial guarantees for subsidiaries' growth

Shanghai Runda Medical Technology has provided new guarantees totaling RMB 23,030.41 million for its subsidiaries in October 2025, bringing the cumulative outstanding guarantee balance to RMB 216,094.45 million. This initiative, approved by the board and shareholders, supports the subsidiaries' operational and project development needs, ensuring continued growth for the group. The company's total external guarantees currently stand at RMB 512,100.00 million, representing 117.60% of its latest audited net assets.

The guarantees are primarily for full and majority-owned subsidiaries, including Hangzhou Runda Medical Management Co., Ltd., Runda Medical Supply Chain Management (Hangzhou) Co., Ltd., Anhui Zefen Biotechnology Co., Ltd., Shanghai Runda Rongjia Biotechnology Co., Ltd., and Shanghai Huizhong Rongjia Medical Laboratory Co., Ltd. These entities' asset-liability ratios exceed 70%, and the guarantees are designed to meet their financing requirements.

The company's total guarantees to its subsidiaries amount to RMB 422,100.00 million, with an actual outstanding balance of RMB 321,759.90 million. This represents 73.89% of Runda Medical's net assets as of December 31, 2024. All guarantees are within approved limits and there are no overdue guarantees.